Contact Us
Contact Us
Contact Us

Our Leadership

Our leadership team is comprised of seasoned industry veterans who bring deep expertise,
relevant experience, and a proven track record of success across biotechnology,
medical devices, and regenerative medicine.

Our Leadership

Our leadership team is comprised of seasoned industry veterans who bring deep expertise,
relevant experience, and a proven track record of success across biotechnology,
medical devices, and regenerative medicine.

Management Team

Yehiel Tal

Chief Executive Officer

Prof. Oded Shoseyov

Founder and Chief Scientist

Eran Rotem

Deputy CEO & Chief Financial Officer

Jasmine Seror, Ph.D.

Vice President of Product Development

Oren Fahimipoor

Vice President of Operations

Bowman Bagley

Vice President of Commercial , North America

Philippe Bensimon

Vice President of Regulatory Affairs & Quality Assurance

Bar Abelis

Vice President Legal

Board of Directors

Yehiel Tal

CEO, Chairman

Dr. Avri Havron

Board Member

Dr. Elan Penn

Board Member

Alisa Lask

Board Member

Yehiel Tal

CEO, Chairman

Dr. Avri Havron

Board Member

Dr. Elan Penn

Board Member

Alisa Lask

Board Member

Joseph Zarzewsky

Board Member

Hugh Evans

Board Member

Hugh Evans

Board Member

Joseph Zarzewsky

Board Member

Clinical and Scientific Advisory Board

Dr. Sachin M. Shridharani

MD, FACS: LUXURGERY

Dr. Jason Bloom MD, FACS

Bloom Facial Plastic Surgery

Dr. Daniel Gould MD, PhD

Beverly Hills Plastic Surgery

Dr. Sachin M. Shridharani

MD, FACS: LUXURGERY

Dr. Jason Bloom MD, FACS

Bloom Facial Plastic Surgery

Dr. Daniel Gould MD, PhD

Beverly Hills Plastic Surgery

Prof. Ofer Levy

MD MCh (Orth) FRCS

Prof. Shay Soker

Wake Forest Institute for Regenerative Medicine

Prof. Ofer Levy

MD MCh (Orth) FRCS

Prof. Shay Soker

Wake Forest Institute for Regenerative Medicine

Prof. Ofer Levy

MD MCh (Orth) FRCS

Prof. Shay Soker

Wake Forest Institute for Regenerative Medicine

Yehiel Tal

Chief Executive Officer

Yehiel is a seasoned executive in the biomedical field and brings over two decades of management experience in both high-tech and biotech companies.

He joined CollPlant in 2010 and prior to this, Yehiel served as CEO and Co-founder of Regentis Biomaterials Ltd.; Vice-President of Business Development at ProChon BioTech Ltd.; Vice President of Marketing and Business Development at OrthoScan Technologies Ltd.; and Director of Business Development and Business Unit Manager at Kulicke and Soffa Industries, Inc.

Yehiel holds a BSc and an MSc degree in Mechanical Engineering from the Technion-Israel Institute of Technology.

Prof. Oded Shoseyov

Founder and Chief Scientist

Oded is a faculty member of the Hebrew University of Jerusalem and has accumulated experience with plant molecular biology and protein engineering. He has authored more than 300 scientific publications and is the inventor of 94 patents.

He received the Outstanding Scientist Polak Award in 2002, the 1999 and 2010 Kay Award for Innovative and Applied Research and the 2012 Israel Prime Minister Citation for Entrepreneurship and Innovation. In addition to CollPlant, Oded is the scientific founder of 15 companies, among them CBD-Technologies/FuturaGene, SP Nano Ltd., Melodea Ltd., Valentis Nanotech. Ltd. and Paulee CleanTec Ltd.

Eran Rotem

Deputy CEO & Chief Financial Officer

Eran is a veteran financial executive in the biotech and industrial sectors.

He joined CollPlant in 2012 and prior to this, Eran served as the Chief Financial Officer of Tefron Ltd., a global industrial company traded on both the Tel Aviv Stock Exchange (TASE:TFRN) and on the OTCBB (OTC:TFRFF) in the U.S. He also served as Chief Financial Officer of Healthcare Technologies Ltd. (NASDAQ:HCTL), Gamida MedEquip and Gamida For Life, a group of companies specializing in the development, manufacturing and marketing of clinical diagnostic test kits worldwide and medical equipment and services to the biotech and high tech industries.

Before Gamida, Eran served as a Senior Manager at Ernst & Young. Eran holds a BA in Accounting and Business Administration from the Tel Aviv College of Management and is a Certified Public Accountant.

Jasmine Seror, Ph.D.

Vice President of Research and Development

Jasmine brings extensive experience in regenerative and aesthetic medicine, 3D bioprinting, and collagen-based technologies. She joined CollPlant in 2014 and leads advanced R&D and product development, translating recombinant human collagen and protein-based biomaterials into innovative medical and aesthetic products. Her expertise spans biomaterials, proteins, cell–material interactions, tissue regeneration, medical devices, and advanced 3D bioprinting platforms. She oversees the full development lifecycle from early research through clinical and commercial readiness, combining strong scientific leadership with strategic product development to guide multidisciplinary teams and shape CollPlant’s innovation roadmap. She holds a BSc and MSc in Biomedical Engineering from Politecnico di Milano and a PhD in Chemistry (Materials and Interfaces) from the Weizmann Institute of Science.

Oren Fahimipoor

Vice President of Operations

Oren has more than 15 years of vast experience in leading complex operations in Life Sciences Industry. Before joining Collplant, he was the Business Unit Manager in Omrix Biopharmaceuticals, a Johnson and Johnson company, leading the Tel Hashomer plant operations end-to-end. Prior to this, he led the Ness Ziona Omrix site.

His previous experience includes more than a decade in Teva Pharmaceutical, where he held several leading positions in Teva’s sterile production plant including leading sterile production and packaging of Vials and Syringes. In addition, Oren has hands-on experience as a researcher in Bio Generics R&D, developing four Biosimilar products including scale up processes and handling technical aspects of the drug development.

Oren holds a BSc in Biotechnology Engineering from the Ben Gurion University and an MBA in Business Management from the Open University of Israel.

Bowman Bagley

Vice President of Commercial, 
US and Canada

Bowman is a biotechnology executive with expertise in collagen-based biomaterials, product development, and commercial strategy.  Prior to joining CollPlant in 2025, he served as CEO of Advanced BioMatrix, where he led global sales and product expansion of purified collagen, bioinks, and other extracellular matrix products used in research, tissue engineering, and drug development. 

In addition to his leadership roles, Bowman advises life science companies on go-to-market strategy, commercial partnerships, and operational growth.  Bowman holds a B.S. in Neuroscience from Brigham Young University and an MBA from the University of Utah.

Philippe Bensimon

Vice President of Regulatory Affairs & Quality Assurance

Philippe brings over two decades of experience in Regulatory Affairs, Quality Assurance and Clinical Affairs in the international medical device industry.
He joined CollPlant in 2011 and prior to this, Philippe served for 14 years as Director of RA/QA/CA at InterVascular Datascope (now Maquet-Getinge), a manufacturer of cardiovascular long-term implants.

Philippe was also with 3M Medical, as Manager of Regulatory Affairs. Philippe holds a PharmD Degree from the University of Pharmacy in Marseille, France.

Bar Abelis

Vice President Legal

Bar brings extensive expertise in corporate governance, capital markets, commercial transactions, and legal strategy for both private and publicly traded companies. She joined CollPlant in 2023 as General Counsel, following her role as Senior Legal Counsel at IM Cannabis Corp. (NASDAQ: IMCC), where she led complex M&A transactions, negotiated international commercial agreements, and oversaw public company compliance and regulatory filings across multiple jurisdictions.

Bar began her legal career at Goldfarb Gross Seligman, one of Israel’s leading law firms, where she specialized in M&A and capital markets. With experience in both private practice and senior in-house legal roles, Bar combines strong legal knowledge with a sharp business mindset to deliver practical, business-oriented legal solutions. Bar holds an LL.B. and an MBA in Finance from Bar-Ilan University and is a member of the Israeli Bar.

Dr. Avri Havron

Board Member

Dr. Havron joined our board of directors in May 2016 bringing with him his extensive experience in the biotechnology sector. Since 2011, Dr. Havron has been serving as an external director at Kamada as well as being a member of their company audit and compensation committees.

From 2005, Dr. Havron was the CEO and Director of PROLOR Biotech Inc. (NYSE MKT: PBTH; TASE: PROL) until it was acquired by OPKO Health Inc. in 2013. Dr. Havron also served as the Vice President and Chief Technology Officer of Clal Biotechnology Industries Ltd. from 1999 to 2003. From 1987 to 1999, Dr. Havron was the Vice President Manufacturing and Process Development at BioTechnology General Ltd. which is currently a subsidiary of Ferring Pharmaceuticals.

In 1980 he joined the founding team of Interpharm Laboratories Ltd. (a subsidiary of Merck Serono S.A.) and was Director of Research and Development until 1987. Dr. Havron holds a PhD in Bio-Organic Chemistry from the Weizmann Institute of Science and served as Research Fellow at Harvard Medical School between 1978-1980.

Dr. Elan Penn

Board Member

Dr. Elan Penn joined our Board of Directors in January 2018. Dr. Penn has served as CEO and Chairman of Penn Publishing Ltd. since 2001. From 2000 to 2001, Dr. Penn served as VP of Finance and Administration of A.I. Research and Development Ltd.

During the years 1998 through 2000, Dr. Penn served as CEO of Sivan Computer Training Company Ltd. From 1992 to 2000, Dr. Penn served as VP of Finance and Administration of Mashov Computers Ltd. From 1987 to 1991 and again from 1992 to 1997, Dr. Penn served as VP of Finance and Administration of Magic Software Enterprises Ltd. (NASDAQ: MGIC) and from 2005 to 2014 served as an External Director of Magic Software Enterprises Ltd. Dr. Penn previously served as a Director of Telkoor Power Supplies Ltd. (TASE: TLCR) and Nexgen Biofuels Ltd. (Formerly Healthcare Technologies Ltd.)(NASDAQ:NXGN).

Dr. Penn holds a BA degree in Economics from the Hebrew University of Jerusalem and PhD in Management Science from Imperial College, University of London.

Alisa Lask

Board Member

Ms. Lask is the former Vice President and General Manager of US Aesthetics at Galderma. Previously, she was a Senior Director of Global Strategic Marketing of Facial Aesthetics at Allergan. Earlier, she held strategic marketing positions at both Zimmer Biomet and Eli Lilly. Ms. Lask received an M.B.A from the University of Michigan and has a B.A. in marketing from Miami University, Oxford, Ohio.

Joseph Zarzewsky

Board Member

Mr. Joseph Zarzewsky joined our Board of Directors in August 2019. Joseph Zarzewsky has served as the Vice President of Business Development at the Mitrelli Group (“Mitrelli”) since 2010.

Mr. Zarzewsky has served as the Chairman of “SMAD”, a joint venture between Mitrelli and the Harbin Government, China, since 2011. Mr. Zarzewsky has also served as the Chairman of the Investment Committee of the Harbin Israel Fund since 2012, and as a member of the board of directors of Wize Pharma, Inc. (OTCQB: WIZP) since 2017. He has also previously served as the Vice President of marketing at Clal Insurance Enterprises Holdings Ltd. (TASE: CLIS) and as the Vice President of Marketing for the Israel Postal Authority.

In addition, Mr. Zarzewsky has served as a director of Excellence Underwriter House Ltd. since 2007. In 2008, he was appointed as the Honorary Economic Advisor of the Harbin Government, China. In addition, in 2012, he was honored as an Honorary Citizen of Harbin, China. Mr. Zarzewsky holds an MA in Commercial Law from the University of Tel Aviv in collaboration with the University of California, Berkeley.

Hugh Evans

Board Member

Mr. Hugh Evans joined our board of directors in March 2021, bringing his extensive board, 3D printing technology and investment experience.

Since 2019, Mr. Evans has been serving as a board member at Factory Four. In addition, since 2020, he has been serving as a board member at ZVerse, 3DM, and as a Non-Executive Chairman of Culinary Printworks. From 2010 to 2020, Mr. Evans served as a board member of AquaVenture Holdings (NYSE: WAAS), which was acquired by Culligan International.

In 2019, Mr. Evans founded Additive Manufacturing Ventures Group, and he serves as a managing member. From 2013 to 2019, Mr. Evans served as Senior Vice President of Corporate Development & Digitization at 3D Systems (NYSE: DDD). Previously, from 1992 to 2013, he served as a portfolio manager at T. Rowe Price Associates (NASDAQ: TROW).

Mr. Evans holds a BA in Psychology from the University of Virginia and an MBA from the Stanford Graduate School of Business.

Dr. Sachin M. Shridharani

MD, FACS: LUXURGERY

Dr. Sachin M. Shridharani is a Harvard educated, Johns Hopkins trained, Manhattan-based plastic surgeon, board certified by The American Board of Plastic Surgery and founder of LUXURGERY – the confluence of luxury and aesthetic surgery. Furthermore, he is Associate Clinical Professor of Plastic Surgery at Washington University – St. Louis School of Medicine.

Dr. Shridharani has co-authored over 300 peer-reviewed articles, textbook chapters, and abstracts on the topics of Plastic Surgery in some of the most well-respected medical journals including the Journal of the American Medical Association (JAMA), Plastic and Reconstructive Surgery, and Aesthetic Surgery Journal.

Recognized as an international authority on aesthetic plastic surgery treatments and techniques, Dr. Shridharani serves as an international Global Thought Leader/Key Opinion Leader and has lectured to colleagues on nearly every continent. Furthermore, Dr. S serves as a Principal Investigator for clinical trials.

Dr. Jason Bloom MD, FACS

Bloom Facial Plastic Surgery

Dr. Jason D. Bloom is an Ivy-League trained, double board certified facial plastic & reconstructive surgeon.  Dr. Bloom completed his undergraduate degree at the University of Michigan and then attended the University of Michigan Medical School, where he graduated Cum Laude and was Alpha Omega Alpha (AOA).  Dr. Bloom completed his residency training in Otorhinolaryngology: Head & Neck Surgery at the University of Pennsylvania and went on to further his training with a facial plastic & reconstructive surgery fellowship program at the New York University (NYU) Langone Medical Center.

Currently, Dr. Bloom is a Clinical Assistant Professor of Surgery in the Division of Plastic Surgery at the University of Pennsylvania, an Adjunct Assistant Professor of Otorhinolaryngology: Head & Neck Surgery at the University of Pennsylvania, a Clinical Assistant Professor (Adjunct) of Dermatology at the Temple University School of Medicine and a Clinical Assistant Professor (Adjunct) of Otolaryngology at the Philadelphia College of Osteopathic Medicine (PCOM).  Additionally, Dr. Bloom serves as Co-Director of the Facial Plastic & Reconstructive Surgery Fellowship program through the University of Pennsylvania and American Academy of Facial Plastic & Reconstructive Surgery (AAFPRS).

Dr. Bloom has authored over 40 journal articles and book chapters, and has given numerous presentations at national and international conferences. Dr. Bloom continues to be academically involved with teaching residents, sitting on medical advisory boards for various companies, speaking engagements and performing research studies and clinical trials in the area of facial plastic & reconstructive surgery. These trials have led him to teach physicians, nurses and injectors for a number of the injectables, laser and medical device companies.

Dr. Daniel Gould MD, PhD

Beverly Hills Plastic Surgery

Daniel J. Gould, MD, PhD, FACS is a board-certified plastic surgeon and bioengineer based in Beverly Hills, California. He holds an MD and a PhD in Bioengineering and completed his plastic surgery training at the University of Southern California, followed by advanced fellowship training in aesthetic and reconstructive surgery.

Dr. Gould’s clinical and research interests focus on regenerative medicine, tissue preservation, biomaterials, and advanced surgical techniques aimed at restoring natural anatomy while minimizing tissue trauma. He has authored over 170 peer-reviewed scientific publications and serves on the editorial board of Aesthetic Surgery Journal, where he is also Section Editor for Regenerative Medicine.

In clinical practice, Dr. Gould specializes in facial rejuvenation, breast surgery, and body contouring, with an emphasis on anatomy-driven, preservation-based approaches. His advisory work reflects a commitment to translating innovative biomaterials and regenerative technologies into safe, evidence-based clinical applications. 

Prof. Ofer Levy

MD, FACS: LUXURGERY MD MCh (Orth) FRCS

Consultant Orthopaedic, Shoulder and Elbow Surgeon. Professor and Chair of the Orthopaedic Surgery Research and Learning Centre – at Brunel University, West London. Director of the Reading Shoulder Unit, an international centre of excellence for shoulder and elbow surgery, Reading, United Kingdom. The unit is recognised worldwide, as a clinical, academic and research centre. Ofer Levy studied medicine at the Hebrew University and Hadassah School of Medicine, Jerusalem and his orthopaedic surgical training at Sheba Medical Centre, Israel.

He is assistant editor, Journal of Shoulder and Elbow Surgery, On the Editorial board of the International Journal of Shoulder Surgery. Special External Examiner, the national university of Ireland and the Royal College of Surgeons in Ireland. Awarded UK national bronze clinical excellence award in 2006. Awarded the Kessel best research award of the British Elbow and Shoulder Society 2010 other distinguished committees.

Professor Shay Soker

Wake Forest Institute for Regenerative Medicine

Prof. Soker brings over 25 years of expertise in the areas of tissue engineering, stem cells, tissue scaffolds, cell differentiation and bioengineering to CollPlant. He currently serves as Professor of Regenerative Medicine and the Scientific Officer for WFIRM. Prof. Soker is an affiliated Professor of Cancer Biology, Physiology & Pharmacology, Biomedical Engineering and Surgical Sciences at the Wake Forest School of Medicine.

Prof. Soker received his Ph.D. from the Technion-Israel Institute for Technology and was a postdoctoral trainee in the Department of Surgical Research at the Boston Children’s Hospital and Harvard Medical School. Working with Michael Klagsbrun and the late Judah Folkman, Prof. Soker’s research focused on vascular biology, with emphasis on angiogenic growth factors and their receptors. Prof. Soker has developed programs in neo-vascularization of bioengineered tissues, stem cell from different sources for tissue engineering in vitro and in vivo and tissue-derived extracellular matrices as scaffolds for whole organ bioengineering. Prof. Soker had published this technology for the engineering of organs and tissues including liver, kidney, pancreas, intestine, cornea and more. Prof. Soker has authored more than 160 scientific publications and reviews and has contributed chapters to numerous books.